F S&P 500
5,157.00 +2.25 (+0.04%) F Dow Jones
38,848.00 +16.00 (+0.04%) F Nasdaq
18,000.00 -0.75 (-0.00%) E-mini Russell 2000 Index Futur
2,047.90 +2.10 (+0.10%) Petróleo
78.11 0.00 (0.00%) Oro
2,301.60 -7.00 (-0.30%)
Biora Therapeutics, Inc. (BIOR)
Fuera de horario:
Biora Therapeutics, Inc.
4330 La Jolla Village Drive
Suite 300
San Diego, CA 92122
United States
833 727 2841
https://www.bioratherapeutics.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 58
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Aditya P. Mohanty M.B.A. | CEO & Director | 984.14k | N/D | 1967 |
| Mr. Eric d'Esparbes | Chief Financial Officer | 748.26k | N/D | 1968 |
| Mr. Clarke Neumann J.D. | Senior VP, General Counsel & Secretary | 724.62k | N/D | 1964 |
| Eric Fox | VP of Finance & Accounting & Treasurer | N/D | N/D | N/D |
| Mr. George Gianakopoulos | Senior Vice President of Sales | N/D | N/D | 1961 |
| Ms. Robyn Hatton | Head of Human Resources | N/D | N/D | N/D |
| Mr. Kevin Howe Ph.D. | Senior VP of Strategic Operations | N/D | N/D | N/D |
| Dr. Sharat Singh Ph.D. | Head of Research | N/D | N/D | 1959 |
| Dr. Paul Shabram M.B.A. | Head of Technical Operations | N/D | N/D | N/D |
| Ms. Ariella Kelman M.D. | Chief Medical Officer | N/D | N/D | N/D |
Descripción
Biora Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing oral biotherapeutics in the United States. The company offers NaviCap, a targeted oral delivery platform for delivery of therapeutics in the gastrointestinal tract to enhance the treatment of inflammatory bowel diseases; and BioJet, a systemic oral delivery platform designs to replace injection with needle-free, oral delivery of large molecules for management of chronic diseases. The company was formerly known as Progenity, Inc. and changed its name to Biora Therapeutics, Inc. in April 2022 to reflect its focus on its therapeutics pipeline. Biora Therapeutics, Inc. was founded in 2010 and is headquartered in San Diego, California.
Gestión corporativa
La calificación ISS Governance QuickScore de Biora Therapeutics, Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
